Ainos, Inc. (AIMD)
NASDAQ: AIMD · Real-Time Price · USD
3.360
+0.110 (3.38%)
At close: Aug 13, 2025, 4:00 PM
3.400
+0.040 (1.19%)
Pre-market: Aug 14, 2025, 8:23 AM EDT
Iteris Revenue
Ainos had revenue of $4.66K in the quarter ending June 30, 2025. This brings the company's revenue in the last twelve months to $110.87K, up 70.25% year-over-year. In the year 2024, Ainos had annual revenue of $20.73K, down -83.02%.
Revenue (ttm)
$110.87K
Revenue Growth
+70.25%
P/S Ratio
94.29
Revenue / Employee
$2,520
Employees
44
Market Cap
13.96M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 20.73K | -101.38K | -83.02% |
| Dec 31, 2023 | 122.11K | -3.40M | -96.53% |
| Dec 31, 2022 | 3.52M | 2.93M | 491.97% |
| Dec 31, 2021 | 594.56K | 578.00K | 3,489.71% |
| Dec 31, 2020 | 16.56K | 4.83K | 41.19% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 422.82B |
| Johnson & Johnson | 90.63B |
| Merck & Co. | 63.62B |
| AbbVie | 58.33B |
| AstraZeneca | 56.50B |
| Novartis AG | 55.19B |
| Eli Lilly and Company | 53.26B |
| Novo Nordisk | 49.11B |
AIMD News
- 16 hours ago - Ainos Reports Second Quarter 2025 Financial Results - Accesswire
- 2 days ago - Ainos to Participate in Fireside Chat with Water Tower Research on August 20, 2025 - Accesswire
- 8 days ago - Ainos Secures $2.1 Million Order With ASE for First Deployment of AI Nose in Semiconductor Manufacturing Setting - Accesswire
- 10 days ago - Ainos Receives TFDA Approval to Initiate Clinical Study of VELDONA for Primary Sjögren's Syndrome - Accesswire
- 21 days ago - Water Tower Research Highlights Ainos' SmellTech Platform AI Nose as Foundational AI Innovation - Accesswire
- 23 days ago - Ainos and ugo Launch World's First AI Nose-Enabled Service Robot Pilots in Seven Sites Across Japan's Industrial Sector - Accesswire
- 4 weeks ago - Ainos Regains Nasdaq Compliance, Sets 90-Day Roadmap to Scale AI Nose Platform in 2026 - Accesswire
- 5 weeks ago - Water Tower Research Highlights Growing Momentum for Ainos' Scent-Tech Solutions and Industrial SmellTech Leadership with New High-Impact Partnerships - Accesswire